Table 2.
Univariate analysis of trial outcome
| No surgical benefit (N = 30) | Surgical benefit (N = 52) | OR (95%-CI) | P value | ||
|---|---|---|---|---|---|
| Subspecialty (%) | Spinal | 17 (56.7) | 23 (44.2) | Ref. | |
| Vascular | 6 (20.0) | 13 (25.0) | 1.60 (0.52–5.35) | 0.42 | |
| Functional | 3 (10.0) | 8 (15.4) | 1.97 (0.49–10.0) | 0.36 | |
| PNS | 2 (6.7) | 8 (15.4) | 2.96 (0.64–21.3) | 0.20 | |
| Pituitary | 2 (6.7) | 0 (0.0) | NA | ||
| Registered (%) | Not registered | 16 (53.3) | 28 (53.8) | Ref. | |
| Registered | 14 (46.7) | 24 (46.2) | 0.98 (0.40–2.43) | 0.96 | |
| Funding (%) | Non-industry | 20 (66.7) | 28 (53.8) | Ref. | |
| Industry | 5 (16.7) | 8 (15.4) | 1.14 (0.33–4.26) | 0.84 | |
| Unknown | 5 (16.7) | 16 (30.8) | 2.29 (0.75–7.92) | 0.16 | |
| Multicenter (%) | Singlecentre | 9 (30.0) | 21 (40.4) | Ref. | |
| Multicentre | 20 (66.7) | 28 (53.8) | 0.60 (0.23–1.58) | 0.30 | |
| NA | 1 (3.3) | 3 (5.8) | 1.29 (0.12–14.09) | 0.84 | |
| Masking (%) | Open label | 16 (53.3) | 33 (63.5) | Ref. | |
| Single blind | 9 (30.0) | 17 (32.7) | 0.92 (0.34–2.56) | 0.86 | |
| Double blind | 5 (16.7) | 2 (3.8) | 0.19 (0.03–1.01) | 0.07 | |
| Number of patients (%) | < 100 | 13 (43.3) | 29 (55.8) | Ref. | |
| ≥ 100 | 17 (56.7) | 23 (44.2) | 0.61 (0.24–1.49) | 0.28 | |
| Change in primary outcome measure (%) | No change | 14 (46.7) | 19 (36.5) | Ref. | |
| Change | 1 (3.3) | 4 (7.7) | 2.95 (0.38–61.1) | 0.36 | |
| Unknown | 15 (50.0) | 29 (55.8) | 1.42 (0.56–3.64) | 0.46 | |
| Change in secondary outcome measure (%) | No change | 8 (26.7) | 14 (26.9) | Ref. | |
| Change | 5 (16.7) | 9 (17.3) | 1.03 (0.26–4.34) | 0.97 | |
| Unknown | 17 (56.7) | 29 (55.8) | 0.97 (0.33–2.77) | 0.96 | |
| Jadad (%) | Jadad < 3 | 11 (36.7) | 27 (51.9) | Ref. | |
| Jadad ≥ 3 | 19 (63.3) | 25 (48.1) | 0.54 (0.21–1.33) | 0.18 | |
| Jadad < 4 | 25 (83.3) | 51 (98.1) | Ref. | ||
| Jadad ≥ 4 | 5 (16.7) | 1 (1.9) | 0.10 (0.01–0.89) | 0.01 | |